Evidence map›Paper›PMID 36099308›Full record

ArticlePloS one2022

Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.

Yvonne A Nartey, Samuel O Antwi, Ansumana S Bockarie, Lindsey Hiebert, Henry Njuguna, John W Ward, Yaw A Awuku, Amelie Plymoth, Lewis R Roberts

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Yvonne A NarteyDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0003-2891-3082
Samuel O AntwiDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida, United States of America.ORCID 0000-0003-2372-9489
Ansumana S BockarieDepartment of Internal Medicine, University of Cape Coast School of Medical Sciences, Cape Coast, Ghana.ORCID 0000-0003-1173-1493
Lindsey HiebertCoalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, United States of America.
Henry NjugunaCoalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, United States of America.
John W WardCoalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, United States of America.
Yaw A AwukuDepartment of Internal Medicine, University of Health and Allied Sciences, Hohoe, Ghana.
Amelie PlymothDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Lewis R RobertsDepartment of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America.
The Task Force for Global Health · USUniversity of Cape Coast · GHKarolinska Institutet · SEMayo Clinic · USMayo Clinic in Florida · USUniversity of Health and Allied Sciences · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver-related diseases, including liver cirrhosis and hepatocellular carcinoma (HCC), are significant causes of mortality globally. Specific causes and predictors of liver-related mortality in low resource settings require assessment to help inform clinical decision making and develop strategies for improved survival. The objectives of this study were to determine the proportion of liver-related deaths associated with liver cirrhosis, HCC, and their known risk factors, and secondly to determine predictors of in-hospital mortality among cirrhosis and HCC patients in Ghana. We first performed a cross-sectional review of death register entries from 11 referral hospitals in Ghana to determine the proportion of liver-related deaths and the proportion of risk factors associated with these deaths. Secondly, we conducted a retrospective cohort review of 172 in-patient liver cirrhosis and HCC cases admitted to a tertiary referral centre and determined predictors of in-hospital mortality using binary logistic regression and Kaplan-Meier survival analysis. In total, 8.8% of deaths in Ghanaian adults were due to liver-related causes. The proportion of liver-related deaths attributed to HBV infection was 48.8% (95% CI: 45.95-51.76), HCV infection was 7.0% (95% CI: 5.58-8.45), HBV-HCV co-infection 0.5% (95% CI: 0.1-0.9) and alcohol was 10.0% (95% CI: 8.30-11.67). Of 172 cases of HCC and liver cirrhosis, the in-patient mortality rate was 54.1%. Predictors of in-patient mortality in cirrhotic patients were increasing WBC (OR = 1.14 95% CI: 1.00-1.30) and the revised model for end-stage liver disease with sodium (MELD-Na) score (OR = 1.24 95% CI: 1.01-1.54). For HCC patients, female sex (OR = 3.74 95% CI: 1.09-12.81) and hepatic encephalopathy (grade 1) were associated with higher mortality (OR = 5.66 95% CI: 1.10-29.2). In conclusion, HBV is linked to a high proportion of HCC-related deaths in Ghana, with high in-hospital mortality rates that require targeted policies to improve survival.

Indexed as

Carcinoma, HepatocellularEnd Stage Liver DiseaseHepatitis CLiver NeoplasmsAdultCross-Sectional StudiesFemaleGhanaHospitalsHumansLiver CirrhosisPrevalenceRetrospective StudiesRisk FactorsSeverity of Illness Index

Identifiers

PMID36099308
PMCPMC9469955
OpenAlexW4295453556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.